Peimine ameliorates LPS-induced acute lung injury by regulating Nrf2 and NF-κB pathways

Hui Huang1, Guanhua Wang1, Dali Zeng1

  • 1Department of Pharmacy, Integrated Traditional Chinese and Western Medicine Hospital of Wenzhou Wenzhou 325000, Zhejiang, China.

Abstract

Insights

Peimine (PM) protects against lipopolysaccharide (LPS)-induced acute lung injury (ALI) by reducing inflammation and oxidative stress. It achieves this by inhibiting the NF-κB pathway and activating the Nrf2 pathway.

Area of Science:

  • Pharmacology
  • Toxicology
  • Immunology

Background:

  • Acute lung injury (ALI) is a severe inflammatory condition with high mortality.
  • Lipopolysaccharide (LPS) is a potent inducer of ALI, triggering inflammatory responses.
  • Peimine (PM) is a traditional Chinese medicine alkaloid with potential therapeutic properties.

Purpose of the Study:

  • To evaluate the protective effects of Peimine (PM) against LPS-induced ALI in a mouse model.
  • To elucidate the underlying molecular mechanisms of PM's action, focusing on inflammatory and oxidative stress pathways.

Main Methods:

  • Mice were treated with varying doses of PM before LPS challenge to induce ALI.
  • Lung injury was assessed by wet-to-dry ratio, histology, and inflammatory cytokine levels (TNF-α, IL-6, IL-1β).
  • NF-κB and Nrf2 pathway activation, oxidative stress markers (MDA, ROS), and antioxidant enzyme expression (HO-1, SOD2) were analyzed via Western blot and RT-PCR. RAW264.7 cells were used for mechanistic studies.

Main Results:

  • PM treatment significantly reduced lung W/D ratio, pathological damage, and inflammatory cytokine levels.
  • PM inhibited LPS-induced oxidative stress markers (MDA, ROS) and enhanced antioxidant enzyme expression.
  • PM suppressed NF-κB activation while promoting Nrf2 pathway activation, which was crucial for its protective effects.

Conclusions:

  • Peimine (PM) demonstrates significant protective effects against LPS-induced ALI in mice.
  • PM ameliorates lung injury by inhibiting the pro-inflammatory NF-κB pathway and activating the antioxidant Nrf2 pathway.
  • These findings highlight PM as a potential therapeutic agent for ALI.